Dhea prostate enlargement

Dutasteride was patented in 1996 [36] and was first described in the scientific literature in 1997. [37] It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the . market the following year under the brand name Avodart. [37] Dutasteride has subsequently been introduced in many other countries as well, including throughout Europe and South America . [37] The patent protection of dutasteride expired in November 2015 and the drug has since become available in the . in a variety of low-cost generic formulations . [36]

DHT is a potent agonist of the AR, and is in fact the most potent known endogenous ligand of the receptor. It has an affinity (K d ) of to  nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (K d = to  nM) [43] and 15–30 times higher than that of adrenal androgens . [44] In addition, the dissociation rate of DHT from the AR is 5-fold slower than that of testosterone. [45] The EC 50 of DHT for activation of the AR is  nM, which is about 5-fold stronger than that of testosterone (EC 50 =  nM). [46] In bioassays , DHT has been found to be - to 10-fold more potent than testosterone. [43]

Dhea prostate enlargement

dhea prostate enlargement


dhea prostate enlargementdhea prostate enlargementdhea prostate enlargementdhea prostate enlargementdhea prostate enlargement